蛋白激酶 Cβ和线粒体轴作为自噬的关键调节因子。
PRKCB/protein kinase C, beta and the mitochondrial axis as key regulators of autophagy.
机构信息
Department of Morphology, Surgery and Experimental Medicine; Section of General Pathology; Interdisciplinary Center for the Study of Inflammation (ICSI); Laboratory for Technologies of Advanced Therapies (LTTA); University of Ferrara; Ferrara, Italy.
出版信息
Autophagy. 2013 Sep;9(9):1367-85. doi: 10.4161/auto.25239. Epub 2013 Jun 11.
Autophagy is the major intracellular system of degradation, and it plays an essential role in various biological events. Recent observations indicate that autophagy is modulated in response to the energy status of the mitochondrial compartment. However, the exact signaling mechanism that controls autophagy under these conditions remains unclear. In this study, we report that the activation of protein kinase C β (PRKCB), a member of the classical PRKCs, negatively modulates the mitochondrial energy status and inhibits autophagy. Furthermore, cells treated with a pharmacological PRKCB inhibitor, and prkcb knockout MEFs showed an increase in autophagy both in vitro and in vivo, as well as an increased mitochondrial membrane potential (Ψm), suggesting a strong involvement of mitochondrial energy in the modulation of the autophagy machinery. Finally, we show that factors that increase the Ψm oppose the PRKCB-dependent inhibition of autophagy. Altogether, these data underscore the importance of PRKCB in the regulation of autophagy; moreover, the finding that a pharmacological modulation of the Ψm modifies autophagy levels may be useful in fighting pathologies (including various types of cancer and neurodegenerative disorders) that are characterized by reduced levels of autophagy.
自噬是主要的细胞内降解系统,它在各种生物事件中起着至关重要的作用。最近的观察表明,自噬受到线粒体区室能量状态的调节。然而,在这些条件下控制自噬的确切信号机制仍不清楚。在这项研究中,我们报告说,蛋白激酶 Cβ(PRKCB)的激活,经典 PRKCs 的成员之一,负调控线粒体能量状态并抑制自噬。此外,用药理学 PRKCB 抑制剂处理的细胞和 prkcb 敲除 MEFs 在体外和体内均显示自噬增加,以及线粒体膜电位(Ψm)增加,表明线粒体能量在自噬机制的调节中具有很强的作用。最后,我们表明,增加 Ψm 的因素反对 PRKCB 依赖性自噬抑制。总之,这些数据强调了 PRKCB 在自噬调节中的重要性;此外,发现 Ψm 的药理学调节可以改变自噬水平,这可能有助于对抗以自噬水平降低为特征的病理学(包括各种类型的癌症和神经退行性疾病)。